Monash University will launch a new study about Friedreich's ataxia
"This project will enable both clinical and quantified gait and upper limb kinematic assessment and may provide a sensitive measure of functional change in FRDA against which the efficacy of novel interventions can be tested down the track".
Saturday, April 16, 2011
Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector.
Gene Therapy, 14 April 2011; doi:10.1038/gt.2011.45.
Gimenez-Cassina A, Wade-Martins R, Gomez-Sebastian S, Corona JC, Lim F, Diaz-Nido J.
Department of Molecular Neurobiology, Centro de Biología Molecular Severo Ochoa, Cantoblanco, Spain.
Keywords: FRDA, gene-based therapies, long-term persistent transgene expression, entire 135 kb FXN genomic DNA locus, bacterial artificial chromosome (iBAC), herpes simplex virus type 1 (HSV-1), -based vector.
Gimenez-Cassina A, Wade-Martins R, Gomez-Sebastian S, Corona JC, Lim F, Diaz-Nido J.
Department of Molecular Neurobiology, Centro de Biología Molecular Severo Ochoa, Cantoblanco, Spain.
Keywords: FRDA, gene-based therapies, long-term persistent transgene expression, entire 135 kb FXN genomic DNA locus, bacterial artificial chromosome (iBAC), herpes simplex virus type 1 (HSV-1), -based vector.
Subscribe to:
Posts (Atom)
